loading
Mink Therapeutics Inc stock is traded at $7.98, with a volume of 4,816. It is up +0.00% in the last 24 hours and down -13.54% over the past month. MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
See More
Previous Close:
$7.98
Open:
$7.9
24h Volume:
4,816
Relative Volume:
0.15
Market Cap:
$31.63M
Revenue:
-
Net Income/Loss:
$-24.77M
P/E Ratio:
-10.93
EPS:
-0.73
Net Cash Flow:
$-17.36M
1W Performance:
-2.21%
1M Performance:
-13.54%
6M Performance:
+2.90%
1Y Performance:
-12.31%
1-Day Range:
Value
$7.807
$8.50
1-Week Range:
Value
$7.54
$8.8789
52-Week Range:
Value
$4.5601
$19.00

Mink Therapeutics Inc Stock (INKT) Company Profile

Name
Name
Mink Therapeutics Inc
Name
Phone
212-994-8250
Name
Address
149 FIFTH AVENUE, NEW YORK
Name
Employee
37
Name
Twitter
Name
Next Earnings Date
2024-08-13
Name
Latest SEC Filings
Name
INKT's Discussions on Twitter

Compare INKT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
INKT
Mink Therapeutics Inc
7.98 31.63M 0 -24.77M -17.36M -0.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Mink Therapeutics Inc Stock (INKT) Latest News

pulisher
Mar 11, 2025

MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday - Defense World

Mar 11, 2025
pulisher
Mar 09, 2025

New Strong Buy Stocks for July 11th - MSN

Mar 09, 2025
pulisher
Mar 05, 2025

The Future of Refractory Multiple Myeloma Therapy: 75+ - openPR

Mar 05, 2025
pulisher
Mar 04, 2025

MiNK Therapeutics, Inc. to Announce Fourth Quarter and Year End 2024 Financial Results on March 18th - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report - GlobeNewswire

Mar 04, 2025
pulisher
Mar 04, 2025

When Will MiNK Therapeutics Reveal Its 2024 Financial Performance? - StockTitan

Mar 04, 2025
pulisher
Feb 28, 2025

What is HC Wainwright’s Estimate for INKT Q1 Earnings? - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

Brokers Set Expectations for INKT FY2029 Earnings - Defense World

Feb 27, 2025
pulisher
Feb 25, 2025

MiNK Therapeutics stock target soars to $35 at H.C. Wainwright By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

MiNK Therapeutics stock target soars to $35 at H.C. Wainwright - Investing.com India

Feb 25, 2025
pulisher
Feb 24, 2025

MiNK Therapeutics presents allo-iNKTs combination data in 2L gastric cancer - TipRanks

Feb 24, 2025
pulisher
Feb 24, 2025

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

MiNK Therapeutics Presents Promising Data from Phase 2 Study of Allo-iNKT Cell Therapy AgenT-797 at AACR Meeting - Nasdaq

Feb 24, 2025
pulisher
Feb 24, 2025

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Can This Novel Cancer Therapy Revolutionize Gastric Cancer Treatment? New Clinical Data Reveals Answer - StockTitan

Feb 24, 2025
pulisher
Feb 24, 2025

How the (INKT) price action is used to our Advantage - Stock Traders Daily

Feb 24, 2025
pulisher
Feb 20, 2025

MiNK Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Nigeria

Feb 20, 2025
pulisher
Feb 20, 2025

MiNK Therapeutics Announces Regained Compliance With Nasdaq Listing Requirements - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

MiNK Therapeutics regains Nasdaq compliance - Investing.com India

Feb 20, 2025
pulisher
Feb 20, 2025

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

MiNK Therapeutics Regains Compliance with Nasdaq Listing Requirements - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

Can MiNK Therapeutics' Nasdaq Compliance Victory Signal a Turnaround for iNKT Cell Therapy Pioneer? - StockTitan

Feb 20, 2025
pulisher
Feb 18, 2025

Stocks Surge Across Health Services and Industry Sectors: Nuvve, Exagen, and Flexsteel Lead the Way - HPBL

Feb 18, 2025
pulisher
Feb 13, 2025

(INKT) Trading Advice - Stock Traders Daily

Feb 13, 2025

Mink Therapeutics Inc Stock (INKT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):